Farlong Pharmaceutical, a vertically integrated, plant-based ingredient and supplement company, has announced the clinical trial results on the effect of Farlong NotoGinseng (Farlong Ginseng Plus Panax Notoginseng extract) on cholesterol and blood pressure.
A randomised, placebo-controlled, double-blind, parallel study on one hundred healthy adults was conducted December 2016 through June 2019. The findings demonstrated that Farlong NotoGinseng supplementation is well tolerated and has a positive influence on reducing the risk of cardiovascular disease by decreasing blood pressure and selectively increasing HDL-C.
Sponsored by Farlong Pharmaceutical and conducted by KGK Science, the primary objective was the difference in serum LDL-C from baseline to week 12 between Farlong NotoGinseng and placebo after 12 weeks of supplementation.
The secondary objectives were the difference in serum LDL-C, blood pressure, triglycerides, HDL-C, total cholesterol and in endothelial vasodilation as measured by the EndoPAT from baseline to week eight and week 12 between Farlong NotoGinseng and placebo.
Over a 12 week period, the participants were given one serving (two capsules) of the investigational product or placebo to take orally at the same time every day, 30 minutes before a meal for 84 days.